Laurus Labs (BOM:540222) ROE % Adjusted to Book Value : 1.43% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Laurus Labs ROE % Adjusted to Book Value?

Laurus Labs's ROE % for the quarter that ended in Mar. 2024 was 7.36%. Laurus Labs's PB Ratio for the quarter that ended in Mar. 2024 was 5.14. Laurus Labs's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was 1.43%.

Laurus Labs ROE % Adjusted to Book Value Historical Data

The historical data trend for Laurus Labs's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laurus Labs ROE % Adjusted to Book Value Chart

Laurus Labs Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

7.87

6.02

2.94

5.47

0.77

Laurus Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															2.61	-	0.70	-	1.43

Competitive Comparison of Laurus Labs's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laurus Labs's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Laurus Labs's ROE % Adjusted to Book Value falls into.

Laurus Labs ROE % Adjusted to Book Value Calculation

Laurus Labs's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	3.94%	/	5.14
	=	0.77%

Laurus Labs's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	7.36%	/	5.14
	=	1.43%

Laurus Labs ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Laurus Labs's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Laurus Labs (BOM:540222) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laurus Labs Ltd (BOM:540222) » Definitions » ROE % Adjusted to Book Value

Traded in Other Exchanges

LAURUSLABS:India

Address

Road No. 7, Banjara Hills, 2nd Floor, Serene Chambers, Hyderabad, TG, IND, 500034

Website

https://www.lauruslabs.com

Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceuticals ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services and others.

Laurus Labs (BOM:540222) Headlines

No Headlines